BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 25002600)

  • 1. Gene deletion speeds mutation rate.
    Cancer Discov; 2014 Jul; 4(7):754. PubMed ID: 25002600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AID/APOBEC cytosine deaminase induces genome-wide kataegis.
    Lada AG; Dhar A; Boissy RJ; Hirano M; Rubel AA; Rogozin IB; Pavlov YI
    Biol Direct; 2012 Dec; 7():47; discussion 47. PubMed ID: 23249472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOBEC-Induced Cancer Mutations Are Uniquely Enriched in Early-Replicating, Gene-Dense, and Active Chromatin Regions.
    Kazanov MD; Roberts SA; Polak P; Stamatoyannopoulos J; Klimczak LJ; Gordenin DA; Sunyaev SR
    Cell Rep; 2015 Nov; 13(6):1103-1109. PubMed ID: 26527001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypermutation by intersegmental transfer of APOBEC3G cytidine deaminase.
    Nowarski R; Britan-Rosich E; Shiloach T; Kotler M
    Nat Struct Mol Biol; 2008 Oct; 15(10):1059-66. PubMed ID: 18820687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cytidine deaminase AID exhibits similar functional properties in yeast and mammals.
    Rogozin IB; Pavlov YI
    Mol Immunol; 2006 Mar; 43(9):1481-4. PubMed ID: 16219354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel activation-induced cytidine deaminase (AID) mutation in Brazilian patients with hyper-IgM type 2 syndrome.
    Caratão N; Cortesão CS; Reis PH; Freitas RF; Jacob CM; Pastorino AC; Carneiro-Sampaio M; Barreto VM
    Clin Immunol; 2013 Aug; 148(2):279-86. PubMed ID: 23803409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-situ cytidine-deaminase activity and chromosome 1P deletion in human neuroblastoma cells.
    Slingerland RJ; Van Gennip AH; Bodlaender JM; Voûte PA; Van Kuilenburg AB
    Anticancer Res; 1997; 17(1A):457-9. PubMed ID: 9066694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of activation-induced cytidine deaminase in inflammation-associated cancer development.
    Marusawa H; Takai A; Chiba T
    Adv Immunol; 2011; 111():109-41. PubMed ID: 21970953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein.
    Löchelt M; Romen F; Bastone P; Muckenfuss H; Kirchner N; Kim YB; Truyen U; Rösler U; Battenberg M; Saib A; Flory E; Cichutek K; Münk C
    Proc Natl Acad Sci U S A; 2005 May; 102(22):7982-7. PubMed ID: 15911774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human cytidine deaminases facilitate hepatitis B virus evolution and link inflammation and hepatocellular carcinoma.
    Deng Y; Du Y; Zhang Q; Han X; Cao G
    Cancer Lett; 2014 Feb; 343(2):161-71. PubMed ID: 24120759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA deamination in immunity.
    Petersen-Mahrt S
    Immunol Rev; 2005 Feb; 203():80-97. PubMed ID: 15661023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction to miniseries on DNA and cancer.
    Kanellopoulos J; Ojcius DM
    Biomed J; 2015; 38(2):101. PubMed ID: 25872559
    [No Abstract]   [Full Text] [Related]  

  • 13. Virus-fighting protein causes mutations in cancers.
    Wong J
    Lancet Oncol; 2013 Aug; 14(9):e347. PubMed ID: 24058970
    [No Abstract]   [Full Text] [Related]  

  • 14. Cancer and complexity: correlations and complementarity.
    Rubin H
    J Surg Oncol; 1998 Sep; 69(1):4-8. PubMed ID: 9762884
    [No Abstract]   [Full Text] [Related]  

  • 15. Mutation hotspots may not be drug targets.
    Carter H
    Science; 2019 Jun; 364(6447):1228-1229. PubMed ID: 31249043
    [No Abstract]   [Full Text] [Related]  

  • 16. Gene deletion: a new target for cancer chemotherapy.
    Frei E
    Lancet; 1993 Sep; 342(8872):662-4. PubMed ID: 8103151
    [No Abstract]   [Full Text] [Related]  

  • 17. Passengers masquerading as cancer drivers.
    Seton-Rogers S
    Nat Rev Cancer; 2019 Sep; 19(9):485. PubMed ID: 31337868
    [No Abstract]   [Full Text] [Related]  

  • 18. UICC Study Group on basic and clinical cancer research: multigene effects influencing each other.
    Burger MM; Friend S
    Int J Cancer; 1996 Nov; 68(3):273-5. PubMed ID: 8903465
    [No Abstract]   [Full Text] [Related]  

  • 19. A method for determining mutation rate and tumor incidence simultaneously.
    BURDETTE WJ
    Cancer Res; 1951 Jul; 11(7):552-4. PubMed ID: 14848827
    [No Abstract]   [Full Text] [Related]  

  • 20. [Possibilities and limitations for protection of the mutation rate in the human].
    LOEFFLER L
    Med Klin; 1958 Jul; 53(28):1236-41. PubMed ID: 13565325
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.